ReviewJournal of translational medicine2025
Cytotoxic T lymphocytes and their dual role in modulating blood-brain barrier integrity in immune-mediated neurological pathologies.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The blood-brain barrier (BBB) is a dynamic, multicellular interface that preserves central nervous system (CNS) homeostasis by restricting entry of pathogens and circulating cells. Cytotoxic T lymphocytes (CTLs), comprising both CD8⁺ and CD4⁺ subsets, are central to adaptive immunity through targeted elimination of infected or transformed cells. However, in immune-mediated neurological disorders, including viral encephalitis, multiple sclerosis, Parkinson’s disease, and glioma, CTLs effector functions can inadvertently compromise BBB integrity. Here, we integrate findings from primary research to delineate three principal mechanisms by which CTLs modulate the BBB: (1) direct cytotoxicity, in which perforin/granzyme release and FasL-Fas interactions induce endothelial cell apoptosis; (2) proinflammatory cytokine signaling, notably IFN‑γ and TNF‑α activation of JAK/STAT and NF‑κB pathways in brain microvascular endothelial cells; and (3) chemokine‑driven leukocyte trafficking, wherein CXCL10 and CCL5 gradients promote CTLs and bystander immune cell migration across the barrier. We further review evidence from in vitro and in vivo models that illustrate both protective and deleterious roles of CTLs at the neurovascular interface. By clearly specifying these mechanisms and their disease‑specific contexts, this review establishes a unified framework for future investigations aimed at preserving BBB function while maintaining effective CTL‑mediated immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.